ARO-APOC3
- Generic Name
- ARO-APOC3
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
ARO-APOC3 is an investigational RNAi therapeutic targeting apolipoprotein C-III (APOC3). It received an Orphan Drug designation by the FDA for the treatment of familial chylomicronemia syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
Arrowhead Pharmaceuticals Submits New Drug Application for Plozasiran Targeting Familial Chylomicronemia Syndrome
Arrowhead Pharmaceuticals submitted an NDA to the FDA for plozasiran, targeting familial chylomicronemia syndrome (FCS), a rare disease with no current FDA-approved treatments. Supported by positive Phase 3 PALISADE study results, plozasiran showed significant triglyceride reduction and decreased acute pancreatitis risk. Arrowhead plans further regulatory submissions in 2025.
Related Clinical Trials:
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath